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Abstract
In conditions of severe gut dysbiosis, there is a risk of developing diseases of the 
host organism in general and of the brain in particular, as evidenced by a growing 
number of studies. This chapter focuses on several groups of low-molecular-weight 
compounds that originate primarily from the gut microbiota. It discusses the results 
of experimental and clinical studies on the effect of microbial metabolites (such 
as short-chain fatty acids, phenolic metabolites of tyrosine, indolic metabolites 
of tryptophan, trimethylamines) on the brain. Several studies have proven that 
the microbial metabolite profiles in the gut and serum are interlinked and reflect 
a disruption of the gut microbial community. Using 16S ribosomal RNA gene 
sequencing, it was found that the gut microbiota of patients with positive or nega-
tive dynamics of neurological status differ taxonomically. The chapter also presents 
data obtained from animal germ-free (GF) models. Many researchers would like to 
consider the gut microbiota as a new therapeutic target, including for the treatment 
of brain diseases, stroke prevention, reduction of neuroinflammation, and more 
successful neurorehabilitation of patients.
Keywords: human microbiome, microbial metabolites, brain damage,  
gut microbiota dysbiosis, mental health, Alzheimer’s disease, autism, stroke,  
critical ill patients, neurorehabilitation
1. Introduction
The human gut microbiome is a community of trillions of microorganisms that 
produce and use many molecules of microbial origin. Normally, the epithelial–
immune–gut barrier supports homeostasis in the host body. The importance of the 
function of the gut microbiota for the host organism allows us to consider it as a 
large but “invisible organ” [1]. In conditions of severe gut dysbiosis, there is a risk of 
developing diseases of the host organism in general and of the brain in particular, 
as evidenced by a growing number of studies [2, 3]. The relevance of studying 
the relationship between the human microbiome and the brain is confirmed by a 
20-fold increase in the number of publications on this topic in the PubMed database 
over the past 10 years (Figure 1).
Today, modern technologies allow us to identify hundreds of types of micro-
organisms in the human gut. Various microbial metabolites are also available 
for measurement in biological material samples, including feces, blood, urine, 
cerebrospinal fluid (CSF), and so on [1–3]. Thus, the possibilities of determining 
microbiota metabolites have expanded to studying their role both in healthy people 
and in patients with various diseases.
Human Microbiome
2
The results of numerous studies show that the gut microbiota affects the devel-
opment of diseases of the central nervous system (CNS), including motor and 
behavioral disorders, neurodegenerative diseases, and cardiovascular and neuroim-
mune-mediated disorders [4–6]. The existence of the microbiome–gut–brain axis 
is now generally recognized. There are several different mechanisms of gut bacteria 
action on the nervous system, including changes in the activity of the stress-related 
hypothalamic–pituitary–adrenal axis, vagus nerve stimulation, and the secretion 
of short-chain fatty acids (SCFAs), which can activate microglial cells and affect 
the permeability of the blood–brain barrier. Evolutionarily conserved signals that 
are involved in the communication between microbiota and the host, which include 
different neuroactive substances, are known as neurochemicals [7].
This chapter focuses on several groups of low-molecular-weight compounds that 
originate primarily from the gut microbiota; their involvement in the interaction of the 
microbiota and the brain has been studied in various experimental and clinical studies.
2. Some molecules involved in the “dialogue”
2.1 Short-chain fatty acids
SCFAs as byproducts of microbiota fermentations are widely studied. It is 
proven that microbial SCFAs (acetate, propionate, butyrate) are involved in the 
energy metabolism of the host [8, 9]. Attempts to cope with metabolic disorders 
in several diseases, including those of the brain, with the help of diets were unsuc-
cessful. One study found different amounts of SCFAs were produced in the guts of 
subjects following the same diet (in terms of the amount and composition of fiber), 
since initially different gut microbiota can trigger different fermentation pathways 
of indigestible carbohydrates [6].
In their review, Dalile et al. [10] describe the effects of SCFAs on cellular systems 
and their interaction with gut–brain signaling pathways through immune, endo-
crine, neural, and humoral mechanisms. The researchers concluded that SCFAs can 
Figure 1. 
Graph showing a 20-fold increase from 2010 to 2019 in the number of publications on the relationship between 
the human microbiome and the brain, according to PubMed. Keyword search results: microbiome and brain, 
microbiome and behaviour.
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penetrate the blood–brain barrier (BBB) to directly interact with brain tissues and 
even contribute to strengthening the integrity of the BBB. In addition, SCFAs pro-
mote serotonin biosynthesis and affect the levels of certain neurotrophic proteins, 
in particular, brain-derived neurotrophic factor (BDNF) and glial cell line-derived 
neurotrophic factor (GDNF) [10]. SCFAs also interfere with pathological mecha-
nisms that are important for Alzheimer’s disease. Thus, SCFAs are able to inhibit the 
formation of soluble beta-amyloid (Aβ) aggregates, which are associated with synap-
tic dysfunction and neurotoxicity. Another study examined the formation of neu-
rotoxic amyloid aggregates (in vitro) and the dose-dependent effects of individual 
SCFAs on this process [11]. The authors call for the development of a new generation 
of probiotics that can metabolize individual dietary fibers to form valerian, butyric, 
and propionic acids and thus reduce the risk of developing neurodegenerative disor-
ders. Unfortunately, animal and in vitro studies using pure fatty acid substances have 
several limitations. The source of SCFAs in vivo is the gut microbiota, and it remains 
unclear whether physiologically significant concentrations of SCFAs can be created 
in the human brain [10].
2.2 Metabolites of aromatic amino acids
Tyrosine and tryptophan are two of the nine essential amino acids that cannot 
be synthesized in the human body. Various metabolic pathways of metabolism of 
aromatic amino acids, such as tyrosine and tryptophan, with different endogenous 
and microbial enzymes, have been previously described [1]. Most often, the 
products of microbial protein biodegradation are associated with negative or toxic 
effects [2, 12]. At the same time, results of various studies suggest that the products 
of anaerobic bacteria from a healthy human gut (metabolites of some Clostridium 
species, Bacteroids, Bifidobacterium, etc.) can be useful [8, 11–13], including for 
brain function, which we discuss later in the chapter.
2.2.1 Phenolic metabolites of tyrosine
Phenylcarboxylic acids (PhCAs) are metabolites of tyrosine that circulate in the 
blood of a healthy human in a constantly low concentration, normally not exceeding 
5 μM [12]. Their microbial origin has been proven [12, 13], as have the causes of a 
significant increase in the number of certain PhCAs, such as p-HPhLA, PhLA, and 
p-HPhAA, in the blood serum of patients with sepsis and sepsis-associated encepha-
lopathy [2]. Serum and fecal profiles of these aromatic microbial metabolites reflect 
gut microbiota disruption in critically ill patients, including those with brain pathol-
ogy. It has been shown that the aromatic microbial metabolite profiles in the gut and 
serum are interlinked and reflect a disruption of the gut microbial community [14].
The taxonomic composition of microbiota and the profile of microbial metabo-
lites of PhCAs were studied in critically ill patients with severe brain damage in 
comparison with other groups of patients, including healthy individuals. Using 
the 16S-ribosomal RNA (16S-rRNA) gene sequencing method, it was found that 
patients with positive dynamics were more characterized by a shift in the balance of 
the gut microbiota towards the predominance of Clostridium taxa [14]. The Glasgow 
Coma Scale (GCS), the National Institutes of Health Stroke Scale (NIHSS), the 
Rivermead Mobility Index Scale, and the Rankin scale were used to assess neurolog-
ical status over time, while the monitoring of serum PhCAs levels was performed by 
gas chromatography–mass spectrometry (GC–MS). Results showed that the positive 
dynamics of neurological status in patients with brain damage was associated with 
serum level of phenylpropionic acid (PhPA) [15]. Based on studies that have estab-
lished that PhPA is the end product of tyrosine metabolism by Clostridia sporogenes 
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[16, 17], we believe that special attention should be paid to further confirmation 
of the involvement of C. sporogenes and studying the pathophysiological role of its 
metabolites in the process of neurorehabilitation.
2.2.2 Indolic metabolites of tryptophan
The essential amino acid tryptophan is the only amino acid that contains the 
structure of an indole-bicyclic compound consisting of a six-membered benzene 
ring connected to a five-membered N-containing pyrrole ring, according to the 
Human Metabolome Database. Tryptophan is absorbed in the small intestine and 
metabolized to kynurenine, serotonin, and melatonin via the host’s endogenous 
pathways. Manipulating heavily depleted tryptophan by way of diet has helped to 
identify patients who are prone to depression or other mood-lowering symptoms 
associated with dysfunctional monoaminergic systems, which can be attributed 
to serotonin deficiency [18]. The part of tryptophan that reaches the colon can be 
catabolized by the gut bacteria resulting in a variety of indole derivatives, such as 
indole, tryptamine, indoleethanol, indolepropionic acid (IPA), indolelactic acid 
(ILA), indoleacetic acid (IAA), skatole, indolealdehyde (IAld), and indoleacrylic 
acid [18, 19]. It is known that some products of bacterial biodegradation of tryp-
tophan can be toxic, for example, indole, as well as indoxyl sulfate (IS), which is 
produced in the liver from indole and has a cytotoxic effect in high concentrations 
[19]. However, research shows that microbial tryptophan metabolites may also 
have a positive impact on host physiology. Tryptophan metabolites can modulate 
both the function of intestinal immune cells and astrocytes in the CNS via the aryl 
hydrocarbon receptor (AHR) [19, 20]. In experimental autoimmune encephalomy-
elitis, the effect of limiting inflammation of the CNS by affecting astrocytes in mice 
treated with antibiotics was shown by adding microbial metabolites of tryptophan 
from the gut microbiota (indole, indoxyl-3-sulfate, IPA, IAld) or the bacterial 
enzyme tryptophanase as AHR agonists [20].
Several studies have noted that IPA and IAA have anti-oxidative and anti-
inflammatory effects. A comparison of the varying data on the blood concentra-
tions of IPA and IAA in patients with different diseases suggests that levels of both 
indole metabolites (IPA and IAA) are reduced in cancer [21]. Unfortunately, no 
studies to date have analyzed the behavior of these metabolites in patients with 
brain tumors, which could be extremely interesting.
There is information about the bacteria of the gut microbiota that is associated 
with the production of specific metabolites of indole. Interestingly, many species 
of anaerobes from different families are able to carry out biotransformation of 
tryptophan in vitro with the formation of IAA (nine species of Clostridium, four of 
Bacteroides, three of Bifidobacterium, and one of Peptostreptococcus). However, the 
ability to produce IPA was found only in three species of Clostridiaceae, and one of 
Peptostreptococcus [16, 21]. At the same time, the results obtained in vivo are more 
modest. In an experimental study of germ-free (GF) mice, production of IPA was 
completely dependent on gut colonization only by C. sporogenes [22].
The severity of stroke outcome in patients is associated with a stroke-induced 
inflammatory response, which in turn is linked with an increase in tryptophan 
catabolism [23, 24]. In Parkinson disease (PD) patients, CSF levels of tryptophan 
and kynurenic acid have been found to be significantly lower compared to healthy 
controls [25]. Future investigations are required to decipher how tryptophan 
metabolites derived from microbes are linked to inflammation in brain disorders 
[5]. The search and modification of methods for accurate measurement of microbial 
tryptophan metabolites continues. The availability of methods for determining 
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concentrations of microbial tryptophan metabolites in serum and CSF is currently 
limited and better quantitative analytical methods targeting a larger variety of 
microbial tryptophan metabolites are needed [26].
2.3 Trimethylamines
The formation of trimethylamine (TMA) occurs in the intestine via biotransfor-
mation of dietary lecithin, choline, or L-carnitine found in certain animal products 
(red meat, egg yolks) and is associated with bacteria of the genera Anaerococcus, 
Clostridium, Escherichia, Proteus, Providencia, and Edwardsiella. It is known that 
TMA is absorbed into the blood and oxidized in the liver by the flavin monooxygen-
ase enzyme to form trimethylamine N-oxide (TMAO) [27]. TMAO is found in CSF, 
indicating its ability to penetrate the blood–brain barrier [28].
The role of TMAO in neurodegenerative diseases, including AD, has been 
investigated extensively in the last five years. A study by Xu et al. [29] analyzed 
20 metabolites that are significantly associated with cognitive decline in patients 
with AD. Potential genetic pathways underlying the strong association between 
TMAO and AD have been investigated. Employing an integrated computational 
approach, researchers identified nine main pathways and found that AD is closely 
related to TMAO. Thus, common genetic pathways underlying known biomark-
ers of AD were identified, with TMAO identified as the top-ranked microbial 
metabolite [29].
Researchers studied TMAO as a biomarker of AD by comparing three groups of 
patients: those with AD clinical syndrome, those with mild cognitive impairment 
(MCI), and cognitively unimpaired individuals. All patient groups had undergone 
lumbar puncture with CSF collection (n = 410), as well as TMAO and other biomark-
ers of AD quantification. Metabolites of microbiota TMAO were significantly elevated 
in CSF and associated with other biomarkers of AD pathology (phosphorylated tau 
and phosphorylated tau/Aβ42) and neuronal degeneration (total tau and neurofila-
ment light chain protein), which confirms gut microbial involvement in AD [30].
2.4 Neurotransmitters
The gut microbiota can produce and/or consume numerous neurotransmit-
ters, including dopamine, norepinephrine, serotonin, or gamma-aminobutyric 
acid (GABA) [4, 31]. Microbiota-dependent effects on gut serotonin significantly 
impact host physiology. For example, it is known that the gut contains the bulk of 
the body’s serotonin (more than 85 percent 5-hydroxytryptamine (5-HT)), but the 
mechanisms that control the metabolism of 5-HT obtained from the gut are still 
unclear. A mammalian experiment showed that indigenous spore-forming bacte-
ria from mouse and human microbiota promote 5-HT biosynthesis from colonic 
enterochromaffin cells, which supply 5-HT to the mucosa, lumen, and circulating 
platelets [32].
3. Special experimental models
Disorders of the gut microbiome have been experimentally documented in some 
brain diseases and stroke. In animal models of AD, PD, and acute stroke, dysbiosis, 
intestinal motility disorders, and/or increased intestinal permeability were demon-
strated. A pro-inflammatory immune response and increased microglia reactivity 
were recorded, compared with a non-diseased condition. Special experimental 
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models of non-microbial or GF animals were used to determine the influence of 
microbiota on the mechanisms of stroke development [33].
From these gnotobiotic animals, it is possible to decipher mechanisms of com-
munication between specific members of the microbiota and the host organism. 
Animals lacking microbiota have extraordinarily different development and physi-
ology than animals hosting commensal bacteria. GF animals have impaired immune 
systems, dysregulated hormone signaling, altered metabolism, and differences in 
neurotransmission from their conventional counterparts [34, 35].
GF mice show an underdeveloped microglia phenotype, which is manifested by 
an incomplete immune response to damage. In an experimental stroke model, GF 
mice showed an incomplete response to brain damage; there was no delineation of 
the damage locus, which was manifested by an increase in the volume of damage 
compared to normal animals. Thus it was determined that the microglia of GF 
animals is morphologically immature [36].
The most common form of dementia is AD, a neurodegenerative disorder associ-
ated with impaired cognitive function. This pathology is characterized by extracel-
lular beta-amyloid (Aβ) plaques and intracellular neurofibrillary tangles composed 
of hyperphosphorylated tau protein [37].
When studying the connection of microbiota with the brain, one of the tasks 
is to find evidence of bacterial participation in AD pathogenesis through the 
formation of amyloid. The results of an experimental model of AD on transgenic 
mice revealed a tendency to the expression of amyloid precursor protein-β (APP). 
When these mice were kept in non-microbial conditions, cerebral β-amyloid 
plaques were less developed than in a normal environment [38]. This experiment 
indicates that the microbiota is involved in triggering adverse changes in the 
brains of transgenic animals, but undoubtedly this depends on the species com-
position and metabolic activity of the bacteria. For example, in AD participants, 
the gut microbiome has a reduced microbial diversity and taxonomically differs 
from the control age and sex correspondences of individuals, in particular, in 
AD compared to the control the number of Firmicutes and Bifidobacterium was 
reduced, but the number of Bacteroidetes was increased. The potential amy-
loidogenic properties of gut bacteria were evaluated and the composition of the 
microbiota and the aggregation of cerebral amyloid-β were also influenced by 
nutrients [11, 39, 40].
Several studies have reported that the microbiome of young mice differs 
significantly from that of older mice, in particular in the ratio of Firmicutes to 
Bacteroidetes. The benefits of the microbiota of young mice were demonstrated 
in an experiment on stroke models, in which transplantation of the gut micro-
biota from young to old mice contributed to an improvement in the outcome of 
stroke [41].
There are some limitations in experiments with GF animals because animals 
with a diverse microbiota have more developed intestinal epithelium than GF ani-
mals, which affects the functioning of the body as a whole. Studying the participa-
tion of microbiota in the functioning of the brain may be not always correct in case 
of comparison of the results obtained in GF and normal animals. The new approach 
avoids these difficulties by using special mice with a modified microbiota, called the 
altered Schaedler flora (ASF) mouse line, because they are colonized by only eight 
species of known bacteria [42].
The majority of research showing that microbiota can influence the nervous sys-
tem has been performed in animals. As such, there is a strong need for well-designed 
human cohorts. Neuroactive compounds of microbial origin can directly modulate 
not only neuronal function and plasticity but also human behavior also [5].
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4. Microbiome and human mental health
The metabolism of tryptophan via the kynurenine pathway leads to the forma-
tion of kynurenine and its neuroactive metabolites, such as 3-hydroxykynurenine, 
kynurenic acid, quinolic acid, and xanthurenic acid. The involvement of kynuren-
ine and its metabolites in the pathogenesis of depressive disorders and schizophre-
nia is being studied [43]. For example, in patients with schizophrenia, an increased 
concentration of 3-hydroxykynurenine in the blood was measured. It is important 
to note that after targeted treatment, the level of this metabolite was normalized. 
This fact indirectly confirms the initial violation of tryptophan metabolism along 
the kynurenine pathway in schizophrenia [44].
According to the 2016 report, “The Five Year Forward View for Mental Health,” 
from the independent Mental Health Taskforce to the NHS in England, mental dis-
orders in the modern world affect every fourth person on the planet [45], which is a 
serious justification for the search for new mechanisms of the influence on mental 
status, including by studying and correcting the microbiome.
A clinical study examined how the gut microbiota and its associated metabolites 
were changed in sleep disorders in children with autism spectrum disorders (ASD). 
There was a decrease in the abundance of Faecalibacterium and Agatobacterium, 
a decrease in 3-hydroxybutyric acid and melatonin, and an increase in serotonin 
levels. These changes can worsen sleep problems and major symptoms in children 
with ASD [46].
Some studies have reported interesting correlations between severity of 
behavioral and gastrointestinal symptoms; others have demonstrated potential 
benefits of probiotics in correcting dysbiosis and reducing the severity of ASD 
symptoms. The general conclusion of these studies is that future research based 
on more randomized controlled studies with larger population sizes and stan-
dardized use of strains, concentration of probiotics, duration of treatments, and 
methods of DNA extraction is needed in this area, which may lead to more robust 
results [47].
According to the World Health Organization, mental disorders are quite com-
mon even in people who lead a seemingly normal lifestyle [48]. At the same time, 
new evidence suggests that less than 10 percent of mental and neurodegenerative 
diseases have a strict genetic etiology. Other predisposing and concomitant factors, 
such as stress, environmental exposures to potentially toxic elements, and other fac-
tors may influence neurometabolism, which may increase the risk for depression, 
autism, sclerosis, PD, and AD [49, 50]. Among these factors, an important place 
is occupied by the gut–brain microbiome relationship at the level of metabolomic 
connections, which allow us to conceptually rethink the causes and mechanisms of 
mental health disorders. Possibly in some categories of people with predisposition, 
the metabolic activity of the gut microbiome may affect not only the development, 
but also the severity of depressive disorder [51].
5. Microbiome and inflammatory events after stroke
The gut inflammatory and immune response can play a key role in the patho-
physiology of severe course and development of complications after stroke. This 
can be judged by studying the mechanisms that occur in the brain when damaged. 
Proinflammatory T cells are often associated with increased inflammatory damage, 
but research of the gut inflammatory and immune response after stroke is still in its 
initial stage [52]. It would be crucial to understand which metabolites from the gut 
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microbiome may affect the degree of brain damage, stroke outcome, and concomi-
tant post-stroke diseases.
An experimental stroke model of GF mice clearly demonstrated the role 
of microbiota. When the mice were recolonized using a dysbiotic post-stroke 
microbiota, an increase in the volume of brain damage and functional deficit was 
observed [53]. In another experimental study, after the use of a cocktail of antibiot-
ics in animals, a significant decrease in the volume of the heart attack in the acute 
phase of stroke was observed. The neuroprotective effect was varied depending on 
the type of antibiotic and correlated with the specific microbial population, rather 
than with the overall bacterial density. In particular, a link was found between the 
large and small size of a brain infarction and the enzymatic pathway of the aromatic 
metabolism in certain strains of Bacteroidetes [54].
In clinical pilot research, which included patients with severity of neurologic 
deficit, the taxonomic composition of the gut microbiota using real-time poly-
merase chain reaction (PCR) was studied. Correlation analysis revealed some con-
nection between microbiology and clinical and laboratory indicators, for example, 
strong negative correlations between Glasgow coma scale scores and the abundance 
of Enterococcus spp. (r = −0.77, p < 0.05). It is interestin that statistically significant 
negative correlations between cortisol levels and the abundance of B. thetaiotao-
micron or F. prausnitzii (r = − 0.57, r = − 0.62, respectively) were detected only in 
patients in a vegetative state [55].
Many authors report dysbiosis in stroke patients [56–58]. Some authors 
associate the dominance of SCFA producers, such as Akkermansia, Odoribacter, 
Ruminococcaceae, and Victivallis, with positive clinical outcomes, while the genus 
Enterobacter had significantly negative correlation with the dynamics of neurological 
status [56]. At the same time, in another study, Akkermansia was reduced in patients 
with cerebral infarction compared with a group of healthy people (p < 0.05) [57].
Pluta et al. [58] presented taxonomic findings in stroke patients. The authors 
launched an active discussion and tried to find explanations for the metabolic 
features of various genera and types of microbes, which, according to various data, 
dominated in the gut of stroke patients. For example, A. muciniphila uses mucin 
to produce acetate, which can be used by other bacteria, such as bacteria from the 
Ruminococcaceae and Odoribacter families, to produce butyrate [59]. However, 
despite many studies in this direction, significant differences and even sometimes 
contradictions of taxonomic findings lead us to conclude that the available informa-
tion is not enough to form a coherent hypothesis.
It should be noted that the data on the taxonomic composition of the gut micro-
biota in most studies were obtained by examining samples from patients in the early 
stages (first and second day) after a stroke. The study of the composition of the gut 
microbiota in patients with a complicated course after stroke is even more relevant. 
These patients need intensive care for a long time due to the development of so-
called chronic critical illness (CCI) [60]. Loss of microbial diversity and pathogen 
domination of the gut microbiota has been noted in such patients [61]. Significant 
differences were found for four genera: Prevotella, Klebsiella, Streptococcus, and 
Clostridium XI [62], which were previously mentioned in connection with some 
neuropsychiatric disorders [63, 64].
The interrelation of factors influencing the development of a CCI as a result of 
long-term violation of the functions of the brain and the gut microbiota has been 
studied [15]. The results confirm the association of taxonomic composition and 
profile of certain aromatic metabolites of the gut microbiota with the progression or 
reversibility of neurological disorders in CCI patients. A gross imbalance of micro-
bial metabolism contributes to the formation of general metabolic dysfunction of 
the human body (Figure 2).
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It is important to remember that microbial diversity and composition of the 
microbiota can be influenced by many personal and environmental factors (diet, 
infection, concomitant diseases, use of antibiotics and other medications, social 
stress, etc.), which can significantly affect the microbiota–gut–brain axis at all 
stages of life [65]. This fact should be considered in the future when developing 
methods to correct the dysfunction of the microbiota.
6. Conclusion
Due to growing interest in the human microbiome and rapid development of 
diagnostic technologies, the taxonomy of the gut microbiota in various diseases 
and disorders of the brain is quickly accumulating. Most researchers are coming to 
a common understanding of the importance of the communication between the 
human microbiome and the brain and are investigating binding small molecules 
as biomarkers and pathophysiological effects. Soon, the significance of particular 
microbial metabolites in the human metabolome will be evaluated in more detail. 
Figuratively speaking, this will allow us to master the “language” of the “dialogue” 
between the microbiome and the brain. Already, many researchers would like to 
consider the gut microbiota as a new therapeutic target, including for the treatment 
of brain diseases, stroke prevention, reduction of neuroinflammation and more 
successful neurorehabilitation of patients.
Figure 2. 
Post-stroke complications and mechanisms of chronic critical illness are closely related to taxonomy disorders 
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